These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 19671735)

  • 21. Predicting and Overcoming Taxane Chemoresistance.
    Rodrigues-Ferreira S; Moindjie H; Haykal MM; Nahmias C
    Trends Mol Med; 2021 Feb; 27(2):138-151. PubMed ID: 33046406
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessing the utility of in vitro microtubule assays for studying mechanisms of peripheral neuropathy with the microtubule inhibitor class of cancer chemotherapy.
    Genualdi C; Feinstein SC; Wilson L; Jordan MA; Stagg NJ
    Chem Biol Interact; 2020 Jan; 315():108906. PubMed ID: 31760042
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An overview on anti-tubulin agents for the treatment of lymphoma patients.
    Barreca M; Stathis A; Barraja P; Bertoni F
    Pharmacol Ther; 2020 Jul; 211():107552. PubMed ID: 32305312
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
    Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel drugs targeting microtubules: the role of epothilones.
    Ferrandina G; Mariani M; Andreoli M; Shahabi S; Scambia G; Ferlini C
    Curr Pharm Des; 2012; 18(19):2793-803. PubMed ID: 22390763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tubulin inhibitors: a patent review.
    Liu YM; Chen HL; Lee HY; Liou JP
    Expert Opin Ther Pat; 2014 Jan; 24(1):69-88. PubMed ID: 24313741
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improving the targeting of tubulin-binding agents: lessons from drug resistance studies.
    Verrills NM; Kavallaris M
    Curr Pharm Des; 2005; 11(13):1719-33. PubMed ID: 15892670
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CCR 20th anniversary commentary: BMS-247550—microtubule stabilization as successful targeted therapy.
    Pabla N; Sparreboom A
    Clin Cancer Res; 2015 Mar; 21(6):1237-9. PubMed ID: 25770292
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Marine Derived Anticancer Drugs Targeting Microtubule.
    De O; Chatterji BP
    Recent Pat Anticancer Drug Discov; 2017; 12(2):102-127. PubMed ID: 28067173
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Taxanes in cancer treatment: Activity, chemoresistance and its overcoming.
    Mosca L; Ilari A; Fazi F; Assaraf YG; Colotti G
    Drug Resist Updat; 2021 Jan; 54():100742. PubMed ID: 33429249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exploring the mechanisms of action of the novel microtubule inhibitor vinflunine.
    Jordan MA; Horwitz SB; Lobert S; Correia JJ
    Semin Oncol; 2008 Jun; 35(3 Suppl 3):S6-S12. PubMed ID: 18538179
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Progress in the study of tubulin inhibitors].
    Shang H; Pan L; Yang S; Chen H; Cheng MS
    Yao Xue Xue Bao; 2010 Sep; 45(9):1078-88. PubMed ID: 21351562
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CENP-E checks in microtubule-drug resistance.
    Chanel-Vos C; Giannakakou P
    Cell Cycle; 2010 Apr; 9(8):1456. PubMed ID: 20421712
    [No Abstract]   [Full Text] [Related]  

  • 34. Ixabepilone: a new microtubule-targeting agent for breast cancer.
    Higa GM; Abraham J
    Expert Rev Anticancer Ther; 2008 May; 8(5):671-81. PubMed ID: 18471040
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epothilones: From discovery to clinical trials.
    Forli S
    Curr Top Med Chem; 2014; 14(20):2312-21. PubMed ID: 25434353
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanism of action of antitumor drugs that interact with microtubules and tubulin.
    Jordan MA
    Curr Med Chem Anticancer Agents; 2002 Jan; 2(1):1-17. PubMed ID: 12678749
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer.
    Trivedi M; Budihardjo I; Loureiro K; Reid TR; Ma JD
    Future Oncol; 2008 Aug; 4(4):483-500. PubMed ID: 18684060
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of novel and potent small-molecule inhibitors of tubulin with antitumor activities by virtual screening and biological evaluations.
    Liu G; Jiao Y; Huang C; Chang P
    J Comput Aided Mol Des; 2019 Jul; 33(7):659-664. PubMed ID: 31165955
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [TUBB3 role in the response of tumor cells to epothilones and taxanes].
    Marczak A; Rogalska A
    Postepy Hig Med Dosw (Online); 2015 Jan; 69():158-64. PubMed ID: 25661915
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular mechanism of action of microtubule-stabilizing anticancer agents.
    Prota AE; Bargsten K; Zurwerra D; Field JJ; Díaz JF; Altmann KH; Steinmetz MO
    Science; 2013 Feb; 339(6119):587-90. PubMed ID: 23287720
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.